|
• Future Growth of oncology drug market is expected to be led by countries such as India, China and others • The market leader, Roche is expected to maintain focus on Emerging Markets and global brands to compete with other players in the industry. Ken Research announced its latest publication on “Asia Oncology Drug Market Outlook to 2019 – Rise in Cancer incidences and Ageing Population to Drive the Demand” which provides a comprehensive analysis of the oncology drug market in Asia. The report covers various aspects such as market size of Asia oncology market, segmentation on the basis of type of modalities, treatment, global and local players, and type of cancer. The report also covers India as well as China oncology drug market in different aspects such as market size, segmentation on the basis of type of treatment, cost of treatment and import and export of anti-cancer drugs in the market. The report is useful for oncology drugs manufacturers, hospitals, government association, retail chains and new players venturing in the market. The Asia oncology market has witnessed a growth in recent years on account of rising demand for anti-cancer drugs fueled by increase in healthcare expenditure, rising awareness and affordability. The surge in growth is majorly originated from growth in Breast and Blood Cancer as a segment of cancer market. The growth is Asia oncology drug market is fueled by growth in markets of India, China and Japan. The growth in these countries has been largely led by the domestic factors such as supportive government policies, increasing demand and entry of new player in oncology drug market. The Asia Oncology drug market is comprised of large companies such as Roche which posses a large product portfolio of oncology drugs. The Asia oncology drug market revenues have grown at a CAGR of 4.3% from 2009-2014. According to the research report, the Asia oncology drug market will grow at a considerable CAGR and will exceed over USD 20 billion by 2017 due to the increasing number of players, rising incidence of cancer and increasing demand for the oncology drugs “Boom in ageing population in China and Japan, rising intake of health insurance and an increase in the out of pocket healthcare expenditure will result in increased revenue of oncology drug market in the Asia, volatility in global product prices, enhancing competition and development of generic drugs are few of the major challenges which will affect the growth of this industry in the future”, according to the Research Analyst, Ken Research. Key Topics Covered in the Report: Oncology Drugs - Market Size by Revenue - Market Segmentation by o Therapeutic Modalities o Generic and Patented Drugs o Local Players and Global Players - Trends and Development - SWOT - Export and Import - Competition and Market Share - Growth Drivers - Future Outlook - Macro Economic Parameters - Key Products Mentioned in the Report - Generic Cancer Drugs - Patented Cancer Drugs - Chemotherapy - Targeted Therapy - Hormone Therapy - Immuno Therapy - Avsatin - Herceptin - Xalkori - Sutent - Gleevec - Arimidex - Revlimid Companies Covered in the Report Global Players - Roche - Pfizer - Novartis - Celgene - GlaxoSmithKline - AstraZeneca - Eli Lily Domestic Players-India - Cipla Ltd - Sun Pharma Pharmaceuticals Ltd - Dr Reddy Laboratories Ltd - NATCO Pharmaceuticals Ltd - Biocon Ltd. Domestic Players-China - Jiang Su Heng Rui Medicine Co. Ltd - Qilu Pharmaceuticals Co. Ltd - Jiangsu Hansoh Pharmaceutical Co. Ltd - Luye Pharma Group Ltd - Livzon Pharmaceutical Group Related Reports: India Single Specialty Hospitals and Clinics Industry Outlook to 2019 - Day Care Specialty Clinics to Impel Growth The US Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth Source: https://www.kenresearch.com/healthcare/pharmaceutical-industry/asia-cancer-drugs-market-research-report/649-91.html Contact: Ken Research Ankur Gupta, Head Marketing & Communications Ankur@kenresearch.com +91-9015378249
Related Articles -
India Oncology Drugs Market, India Cancer Drugs Industry, Cancer Drugs Pipeline Trial Asia,
| 
